Nuvation Bio Inc. (NUVB)
Last Price$2.0(6.2%)
Market Cap$662.1M
NUVB Rating
NUVB Quality rating performance
NUVB Intrinsic Value
Key Highlights:
As of Mar 18, 2025 NUVB Relative Value is $3.9, which is undervalued by 100.6%, compared to current share price of $2.0.
As of Mar 18, 2025 NUVB DCF Value is $3.4, which is undervalued by 74.0%, compared to current share price of $2.0.
NUVB Share Price History
1W (14.4%)
1M (15.5%)
6M (32.4%)
YTD 24.8%
1Y (13.3%)
3Y (64.0%)
5Y (80.4%)
10Y (80.4%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
NUVB Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$662.1M
$168.3M
$7,873.0K
($130.6M)
Shares Outstanding
338M
Employees
1,000K
Growth (CAGR)
N/A
39.2%
68.60%
453.7%
374.1%
(73.38%)
Profitability
6.3%
(2,128.2%)
(7,213.8%)
(1,656.5%)
(1,658.5%)
23.0%
Intrinsic Value
$3.7 (88.4% undervalued)
$3.4
$4.0
$128.5
(100.0%)
(831.4%)
Valuation (LTM)
Return on Capital
(117.5%)
(102.1%)
(2,176.8%)
(33.7%)
(30.9%)
(872.6%)
(872.6%)
Financial Health
($493.8M)
3.8x
(491.4x)
Dividends
Earnings
Aug 04, 2025
BEAT by 85.4%
MISS by 6.7%
5 Beat & 5 Miss
NUVB Stock Financials
NUVB Income Statement Metrics
Annual
Quarterly
LTM
NUVB Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($130.4M) +91.8% YoY
Capital Expenditure (CAPEX)
($162.0K) +134.8% YoY
Free Cash Flow (FCF)
($130.6M) +91.8% YoY
NUVB Income Statement Overview
Annual
Quarterly
LTM
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$7,873.0K 0.0% YoY
Cost of revenue
$7,078.0K 3,088.3% YoY
Operating
expenses
$593.4M 494.5% YoY
Other: $142.9M
NUVB Balance Sheet Overview
Annual
Quarterly
LTM
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$540.6M
Current assets ($526.3M, 97.3% of total)
$502.7M (93.0%)
$16.3M (3.0%)
Other current assets
$7,271.0K (1.3%)
Non-current assets ($14.4M, 2.7% of total)
$0.0 (0.0%)
$2,988.0K (0.6%)
$4,622.0K (0.9%)
Other non-current assets
$6,761.0K (1.3%)
Financial position
($493.8M)
Cash & Short-term
Investments
Total Debt
NUVB Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
NUVB Earnings Surprises
Crunching data... Almost there!
NUVB Dividends
NUVB Dividend Yield
Crunching data... Almost there!
NUVB Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with NUVB
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$662.1M | 5.8 | $3.7 88.4% undervalued | (13.3%) | $7,873.0K | ($130.6M) | 2,882.2% | (1,658.5%) | 6.3% | (2,176.8%) | 1.9% | |
$132.4B | 5.8 | $185.4 63.8% overvalued | 24.5% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$72.4B | 6.4 | $1,022.8 53.8% undervalued | (30.6%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$36.9B | 6.3 | $189.5 69.0% overvalued | 69.0% | $3,154.8M | ($58.8M) | 157.1% | (1.9%) | 74.8% | 67.0% | 0.7% | |
$32.2B | 5.2 | $90.9 62.8% overvalued | 65.7% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$23.9B | 5.9 | $195.6 97.7% undervalued | 6.4% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.9B | 5.5 | $69.3 107.5% undervalued | 14.6% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$14.6B | 6.0 | $0.6 97.1% overvalued | 381.6% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.4B | 7.8 | $529.4 68.5% undervalued | 34.3% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.7B | 6.8 | $49.6 30.6% overvalued | (14.7%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$1,846.9M | 5.5 | $2,609.6 1,051.1% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Nuvation Bio Inc. (NUVB) stock rating?
As of today, Nuvation Bio Inc. has a stock rating of 6 (out of 10), which is considered Good.
is Nuvation Bio Inc. (NUVB) a good stock to buy?
As of today, Nuvation Bio Inc. has a Good stock rating, which is 88.4% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.